A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
← catalyst calendarNCT07065344 · readout in 164 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
500estimated
Sites
21
Countries
Egypt, Iraq, Jordan +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-23 | actual | When the study began enrolling |
| Primary completion | 2027-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hematology
- Diffused Large B Cell Lymphoma
Primary outcome
what the primary-completion date above is the date OFTo describe the treatment patterns for the first line and subsequent therapies for DLBCL patients
measured 22 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed